Roquefort Therapeutics (LON:ROQ) Trading 4.3% Higher – Here’s Why

Roquefort Therapeutics plc (LON:ROQ)’s share price shot up 4.3% on Friday . The company traded as high as GBX 1.80 ($0.02) and last traded at GBX 1.77 ($0.02). 3,842,397 shares changed hands during trading, an increase of 116% from the average session volume of 1,782,012 shares. The stock had previously closed at GBX 1.70 ($0.02).

Roquefort Therapeutics Stock Up 10.9 %

The firm has a market capitalization of £2.40 million, a PE ratio of -1.56 and a beta of 0.05. The company’s 50 day simple moving average is GBX 3.31 and its 200-day simple moving average is GBX 3.76. The company has a debt-to-equity ratio of 12.37, a quick ratio of 3.07 and a current ratio of 0.79.

Insiders Place Their Bets

In related news, insider Stephen Paul West purchased 400,000 shares of the business’s stock in a transaction on Tuesday, February 4th. The stock was acquired at an average price of GBX 3 ($0.04) per share, with a total value of £12,000 ($15,124.78). Corporate insiders own 60.40% of the company’s stock.

Roquefort Therapeutics Company Profile

Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.